In the Clinic
Our lead investigational drug, OP-1250, is a novel oral compound developed to completely antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal.
OP-1250 Pipeline
Target Patient Population
Discovery
Nonclinical
Phase I
Phase II
Phase III
Clinical
Collaboration
Metastatic Breast Cancer
ER+, HER2- MBC
(with and without CNS metastases)
ER+, HER2- MBC
(combination with palbociclib)
ER+, HER2- MBC
(combination with ribociclib)
ER+, HER2- MBC with PIK3CA mutated
(combination with alpelisib)
ER+ with ESR1 mutation(1)
HER2+ Metastatic Breast Cancer with CNS METS
ER+, HER2+ MBC with CNS metastases
Gynecology — Oncology
Endometrial Cancer(1)
Gynecologic malignancies
Discovery Pipeline
Target Patient Population
Discovery
Nonclinical
Phase I
Phase II
Phase III
Clinical
Collaboration
Breast Cancer target
Undisclosed Oncology target